ADCT

ADC Therapeutics SA - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. ADC Therapeutics SA is a commercial-stage biopharmaceutical company focused on antibody drug conjugates (ADCs). Its primary revenue source is the flagship product ZYNLONTA, approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company operates as a single reportable segment and is classified as a non-accelerated filer and smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 27.6% to $23.0 million, driven primarily by a $5.0 million license revenue milestone from Sobi following ZYNLONTA's conditional approval by Health Canada. Product revenue from ZYNLONTA decreased slightly by 2.5% to $17.4 million due to lower sales volume.
• Expense Management: Total operating expenses remained relatively flat at $51.5 million. Research and Development (R&D) expenses increased 12.4% to $28.9 million, largely due to increased spending on preclinical product candidates and next-generation ADCs. Selling and marketing expenses decreased 7.3% due to cost-cutting initiatives.
• Cash Flow: Net cash used in operating activities increased by $12.2 million to $56.3 million. This was primarily attributable to a $7.2 million payment for the 2023 discarded drug rebate and a $4.0 million increase in annual bonus and retention payments.
• Debt and Obligations: The deferred royalty obligation increased to $326.8 million due to accretion of interest. The senior secured term loan balance remained stable at approximately $113.8 million.

Outlook, Risks, and Management Commentary

• Liquidity: Management believes current cash resources of $194.7 million are sufficient to fund operations for at least the next twelve months. The company plans to fund future needs through existing cash, product revenues, milestone payments, and potential additional equity or debt financing.
• Pipeline Updates: The company is advancing ZYNLONTA into earlier lines of therapy and new indications. It has discontinued the Phase 1/2 ADCT-602 clinical trial and the ADCT-601 program. Solid tumor programs targeting Claudin-6 and PSMA are advancing.
• Risks: Key risks include the need to raise additional capital, the impact of the royalty financing agreement with HCR on cash generation, the timing and success of clinical trials, and reliance on third-party manufacturers. The company notes that forward-looking statements are subject to significant uncertainties.
• Unusual Items: The Q1 2024 period included a $3.1 million expense related to the change in fair value of the Deerfield warrant obligation, which was $0 in Q1 2025 as the fair value remained at zero.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $194.7 million cash balance against the $56.3 million quarterly operating cash burn, considering the one-time $7.2 million rebate payment.
• Debt Covenants: Review the restrictive covenants associated with the $113.8 million senior secured term loan and the $326.8 million deferred royalty obligation.
• Revenue Recurrence: Assess the sustainability of the $5.0 million license revenue, which was a one-time milestone payment, versus the slight decline in core product revenue.
• R&D Efficiency: Evaluate the 110% increase in spending on preclinical candidates against the discontinuation of other programs (ADCT-601, ADCT-602) to ensure capital allocation aligns with strategic priorities.
• Share Dilution: Monitor the impact of share-based compensation ($2.4 million expense) and potential future equity financings on shareholder dilution.